{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:44:23Z","timestamp":1788212663824,"version":"build-2803163510"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019341","name":"Medtronic Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019341","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Reactive atrial-based anti-tachycardia pacing (rATP) in pacemakers (PMs) and cardiac resynchronization therapy defibrillators (CRT-Ds) has been reported to prevent progression of atrial fibrillation, and this reduced progression is expected to decrease the risk of complications such as stroke and heart failure (HF). This study aimed to assess the cost-effectiveness of rATP in PMs and CRT-Ds in the Japanese public health insurance system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>We developed a Markov model comprising five states: bradycardia, post-stroke, mild HF, severe HF, and death. For devices with rATP and control devices without rATP, we compared the incremental cost-effectiveness ratio (ICER) from the payer's perspective. Costs were estimated from healthcare resource utilisation data in a Japanese claims database. We evaluated model uncertainty by analysing two scenarios for each device. The ICER was 763 729 JPY\/QALY (5616 EUR\/QALY) for PMs and 1,393 280 JPY\/QALY (10 245 EUR\/QALY) for CRT-Ds. In all scenarios, ICERs were below 5 million JPY\/QALY (36 765 EUR\/QALY), supporting robustness of the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>According to a willingness to pay threshold of 5 million JPY\/QALY, the devices with rATP were cost-effective compared with control devices without rATP, showing that the higher reimbursement price of the functional categories with rATP is justified from a healthcare economic perspective.<\/jats:p><\/jats:sec>","DOI":"10.1093\/europace\/euad003","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T08:53:39Z","timestamp":1674550419000},"page":"1087-1099","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness analysis of cardiac implantable electronic devices with reactive atrial-based antitachycardia pacing"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5290-3282","authenticated-orcid":false,"given":"Takashi","family":"Noda","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , 6-1 Kishibe-Shimmachi, Suita, Osaka 564-8565 , Japan"},{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine and Tohoku University Hospital , 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7862-3967","authenticated-orcid":false,"given":"Nobuhiko","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , 6-1 Kishibe-Shimmachi, Suita, Osaka 564-8565 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9238-5873","authenticated-orcid":false,"given":"Yuji","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Healthcare Economics and Government Affairs, Medtronic Japan Co., Ltd. , 1-2-70 Konan, Minato-ku, Tokyo 108-0075 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Healthcare Economics and Government Affairs, Medtronic Japan Co., Ltd. , 1-2-70 Konan, Minato-ku, Tokyo 108-0075 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Healthcare Economics and Government Affairs, Medtronic Japan Co., Ltd. , 1-2-70 Konan, Minato-ku, Tokyo 108-0075 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8844-4778","authenticated-orcid":false,"given":"Tatsuhiro","family":"Uenishi","sequence":"additional","affiliation":[{"name":"Data Science Department, Medilead, Inc. , 3-20-2 Nishi-Shinjuku, Shinjuku-ku, Tokyo 163-1424 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6871-0680","authenticated-orcid":false,"given":"Hiroko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Data Science Department, Medilead, Inc. , 3-20-2 Nishi-Shinjuku, Shinjuku-ku, Tokyo 163-1424 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1077-6393","authenticated-orcid":false,"given":"Ayako","family":"Shoji","sequence":"additional","affiliation":[{"name":"Data Science Department, Medilead, Inc. , 3-20-2 Nishi-Shinjuku, Shinjuku-ku, Tokyo 163-1424 , Japan"},{"name":"Healthcare Consulting Inc. , 1-8-19 Fujimi, Chiyoda-ku, Tokyo 102-0071 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2908-6974","authenticated-orcid":false,"given":"Jae-Eun","family":"Myung","sequence":"additional","affiliation":[{"name":"Government Affairs and Market Access, Medtronic Korea Ltd. , #534, Teheran-ro, Gangnam-gu, Seoul 06181 , Korea"},{"name":"Department of Pharmaceutical Medicine and Regulatory Science, College of Medicine and Pharmacy, Yonsei University , 50 Yonsei-ro, Seodaemun-gu, Seoul 03722 , Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5760-9285","authenticated-orcid":false,"given":"Kengo","family":"Kusano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , 6-1 Kishibe-Shimmachi, Suita, Osaka 564-8565 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2188\/jea.15.194","article-title":"Rapid increase in estimated number of persons with atrial fibrillation in Japan: an analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000","volume":"15","author":"Ohsawa","year":"2005","journal-title":"J Epidemiol"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijcard.2008.06.029","article-title":"Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination","volume":"137","author":"Inoue","year":"2009","journal-title":"Int J Cardiol"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1160\/TH4-04-0383","article-title":"Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study","volume":"112","author":"Martinez","year":"2014","journal-title":"Thromb Haemost"},{"key":"2023033021221580400_","author":"National Federation of Health Insurance Societies (KENPOREN)"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation [published correction appears in Eur Heart J. 2021 May 14; 42(19):1908] [published correction appears in Eur Heart J. 2021 May 14; 42(19):1925] [published correction appears in Eur Heart J. 2021 May 13]","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","article-title":"Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT","volume":"38","author":"Van Gelder","year":"2017","journal-title":"Eur Heart J"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/europace\/euab193","article-title":"European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology","volume":"24","author":"Aktaa","year":"2022","journal-title":"Europace"},{"key":"2023033021221580400_","first-page":"3250","article-title":"Atrial fibrillation in heart failure: what should we do?","volume":"36","author":"Kotecha","year":"2015","journal-title":"Eur Heart J"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.1994.03520200070038","article-title":"Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction","volume":"272","author":"Baker","year":"1994","journal-title":"JAMA"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke [published correction appears in N Engl J Med. 2016 Mar 10; 374(10):998]","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/europace\/euab232","article-title":"2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy [published correction appears in Europace. 2022 Mar 07]","volume":"24","author":"Glikson","year":"2022","journal-title":"Europace"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.jacc.2018.03.519","article-title":"Progression of device-detected subclinical atrial fibrillation and the risk of heart failure","volume":"71","author":"Wong","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jjcc.2019.10.001","article-title":"Efficacy and safety of new-generation atrial antitachycardia pacing for atrial tachyarrhythmias in patients implanted with cardiac resynchronization therapy devices","volume":"75","author":"Ueda","year":"2020","journal-title":"J Cardiol"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/eurheartj\/ehu165","article-title":"Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial","volume":"35","author":"Boriani","year":"2014","journal-title":"Eur Heart J"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/europace\/euy286","article-title":"Effect of PR interval and pacing mode on persistent atrial fibrillation incidence in dual chamber pacemaker patients: a sub-study of the international randomized MINERVA trial","volume":"21","author":"Boriani","year":"2019","journal-title":"Europace"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.hrthm.2015.04.015","article-title":"New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: results from the MINERVA randomized multicenter international trial","volume":"12","author":"Padeletti","year":"2015","journal-title":"Heart Rhythm"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.hrthm.2015.02.017","article-title":"Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: an analysis of the randomized MINERVA trial","volume":"12","author":"Boriani","year":"2015","journal-title":"Heart Rhythm"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/hpm.2719","article-title":"Reimbursement pricing for new medical devices in Japan: is the evaluation of innovation appropriate?","volume":"34","author":"Tamura","year":"2019","journal-title":"Int J Health Plann Manage"},{"key":"2023033021221580400_","first-page":"311","article-title":"Coverage with evidence development programs for medical technologies in Asia-pacific regions: A case study of Japan and South Korea","volume":"4","author":"Myung","year":"2021","journal-title":"JMA J"},{"key":"2023033021221580400_","author":"Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health (C2H)"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N Engl J Med"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2005.09.016","article-title":"Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial [published correction appears in J Am Coll Cardiol.2008 Jun 3; 51(22): 2197. Ghali, Jalil [corrected to Ghali, Jalal]]","volume":"46","author":"Carson","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"2023033021221580400_","author":"Ministry of Health, Labour and Welfare"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.hrthm.2014.08.019","article-title":"Newly detected atrial high rate episodes predict long-term mortality outcomes in patients with permanent pacemakers","volume":"11","author":"Gonzalez","year":"2014","journal-title":"Heart Rhythm"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1253\/circj.CJ-20-0024","article-title":"Two-year recurrence after first-ever stroke in a general population of 1.4 million Japanese patients- the shiga stroke and heart attack registry study","volume":"84","author":"Takashima","year":"2020","journal-title":"Circ J"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013753","article-title":"Differences between determinants of in-hospital mortality and hospitalisation costs for patients with acute heart failure: a nationwide observational study from Japan","volume":"7","author":"Sasaki","year":"2017","journal-title":"BMJ Open"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","article-title":"Context and considerations for use of two Japanese real-world databases in Japan: medical data vision and Japanese medical data center","volume":"9","author":"Laurent","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jval.2021.03.010","article-title":"Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings","volume":"24","author":"Shiroiwa","year":"2021","journal-title":"Value Health"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1524-4733.2008.00425.x","article-title":"Utility estimates for decision-analytic modeling in chronic heart failure\u2013health states based on New York Heart Association classes and number of rehospitalizations","volume":"12","author":"G\u00f6hler","year":"2009","journal-title":"Value Health"},{"key":"2023033021221580400_","author":"Medtronic"},{"key":"2023033021221580400_","author":"Medtronic"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jamaneurol.2021.4346","article-title":"Twenty-Year change in severity and outcome of ischemic and hemorrhagic strokes","volume":"79","author":"Toyoda","year":"2022","journal-title":"JAMA Neurol"},{"key":"2023033021221580400_","author":"Ministry of Health, Labour and Welfare"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJM200005113421902","article-title":"Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators","volume":"342","author":"Connolly","year":"2000","journal-title":"N Engl J Med"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1540-8167.2008.01320.x","article-title":"Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events","volume":"20","author":"Botto","year":"2009","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1056\/NEJMoa013040","article-title":"Ventricular pacing or dual-chamber pacing for sinus-node dysfunction","volume":"346","author":"Lamas","year":"2002","journal-title":"N Engl J Med"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/joa3.12377","article-title":"Trends in the use of implantable cardioverter-defibrillator and cardiac resynchronization therapy device in advancing age: analysis of the Japan cardiac device treatment registry database","volume":"36","author":"Yokoshiki","year":"2020","journal-title":"J Arrhythm"},{"key":"2023033021221580400_"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacep.2015.02.018","article-title":"Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials","volume":"1","author":"Al Halabi","year":"2015","journal-title":"JACC Clin Electrophysiol"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1161\/CIRCULATIONAHA.115.019406","article-title":"Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial","volume":"133","author":"Di Biase","year":"2016","journal-title":"Circulation"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/CIRCEP.114.001938","article-title":"Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis","volume":"7","author":"Anselmino","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019701","article-title":"Complications associated with catheter ablation in patients with atrial fibrillation: a report from the JROAD-DPC study","volume":"10","author":"Yokoyama","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.hrthm.2012.06.007","article-title":"Incidence, characteristics, and outcome of left atrial tachycardias after circumferential antral ablation of atrial fibrillation","volume":"9","author":"Wasmer","year":"2012","journal-title":"Heart Rhythm"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/pace.13696","article-title":"Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias","volume":"42","author":"Crossley","year":"2019","journal-title":"Pacing Clin Electrophysiol"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz386","article-title":"Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort","volume":"40","author":"Kim","year":"2019","journal-title":"Eur Heart J"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-158-5-201303050-00007","article-title":"Cognitive impairment associated with atrial fibrillation: a meta-analysis","volume":"158","author":"Kalantarian","year":"2013","journal-title":"Ann Intern Med"},{"key":"2023033021221580400_","article-title":"Atrial fibrillation catheter ablation improves 1-year follow-up cognitive function, especially in patients with impaired cognitive function","volume":"12","author":"Jin","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/01.CIR.0000151810.69732.41","article-title":"Cost-effectiveness of dual-chamber pacing compared with ventricular pacing for sinus node dysfunction","volume":"111","author":"Rinfret","year":"2005","journal-title":"Circulation"},{"key":"2023033021221580400_","first-page":"1","article-title":"Dual-chamber pacemakers for treating symptomatic bradycardia due to sick sinus syndrome without atrioventricular block: a systematic review and economic evaluation","volume":"19","author":"Edwards","year":"2015","journal-title":"Health Technol Assess"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.hrthm.2018.05.024","article-title":"Cost-effectiveness analysis of magnetic resonance imaging-conditional pacemaker implantation: insights from a multicenter study and implications in the current era","volume":"15","author":"Mar","year":"2018","journal-title":"Heart Rhythm"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jchf.2016.10.014","article-title":"Economic value and cost-effectiveness of cardiac resynchronization therapy among patients with mild heart failure: projections from the REVERSE long-term follow-up","volume":"5","author":"Gold","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jjcc.2021.12.016","article-title":"Cost-effective analysis of automated programming optimization in cardiac resynchronization therapy: Holistic Markov modelling","volume":"79","author":"Noda","year":"2022","journal-title":"J Cardiol"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/europace\/eur348","article-title":"Arrhythmia-induced cardiomyopathies: the riddle of the chicken and the egg still unanswered?","volume":"14","author":"Simantirakis","year":"2012","journal-title":"Europace"},{"key":"2023033021221580400_","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3390\/jcm8091411","article-title":"Tachycardiomyopathy in patients without underlying structural heart disease","volume":"8","author":"Stronati","year":"2019","journal-title":"J Clin Med"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/3\/1087\/49703911\/euad003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/3\/1087\/49703911\/euad003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T04:38:22Z","timestamp":1701664702000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/25\/3\/1087\/7000096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,24]]},"published-print":{"date-parts":[[2023,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euad003","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2023,1,24]]}}}